No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.

• Kaken Pharmaceutical Co., Ltd.
• China Traditional Chinese Medicine Holdings Co. Limited
• Amphastar Pharmaceuticals, Inc.
• Collegium Pharmaceutical, Inc.
• Hunan Warrant Pharmaceutical Co.,Ltd
• Guizhou Bailing Group Pharmaceutical Co., Ltd.
• Center Laboratories, Inc.
• Beijing Sun-Novo Pharmaceutical Research Co., Ltd.